Related Experiment Video
Updated: Mar 30, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Genetic variations in the PI3K/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in
Lu Guo1, Hua Wu1, Jinghong Zhu2
1Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou City, 730000, Gansu Province, China.
Aims:
Cervical cancer is one of the most frequent malignant tumours in women. The PI3K/Akt pathway plays a role in chemoresistance to platinum-based neoadjuvant chemotherapy (NAC). The objective of this study was to evaluate the association between genetic polymorphisms in the PI3K/Akt pathway and chemotherapeutic outcomes following platinum-based NAC in Northwestern Chinese Han patients with squamous cervical cancer (SCC).
Main Methods:
In total, 17 tagging single nucleotide polymorphisms (tSNPs) in four genes (PIK3CA, Akt1, Akt2, PTEN) were identified as being associated with chemotherapeutic response in 259 patients with stage IB2-IIB SCC. Each of these patients received more than two cycles of NAC. These tSNPs were genotyped by the Sequenom MassArray system.
Key Findings:
The heterozygous genotype of two loci in the PIK3CA gene (rs3729679: uncorrected P=0.022 and rs12494623: uncorrected P=0.018) was associated with an increased risk of chemoresistance in SCC patients. The stratified analysis also showed that these same SNP polymorphisms were associated with a poor response to NAC in the cisplatin-based subgroup. Furthermore, NAC non-responders had a higher frequency of the rs10416620 and rs62107593 G alleles in the Akt2 gene (rs10416620 and rs62107593: uncorrected P=0.037). The rs34716810 A allele was associated with a poor response to chemotherapy (uncorrected P=0.037). Moreover, rs2498786 (uncorrected P=0.036) and the GGCC haplotype of polymorphisms in Akt1 showed a high risk for non-response to NAC (uncorrected P=0.018).
Significance:
The findings from this study demonstrate that genetic polymorphisms in the PI3K/Akt pathway are associated with sensitivity to platinum-based chemotherapy in SCC patients.
More Related Videos
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

